ABEO Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
8.7M
+60.9%
5.4M
400.0K
Cost of Revenue
2.7M
+158.2%
1.0M
+113.9%
488.0K
0
0
Gross Profit
6.0M
+37.7%
4.4M
+996.7%
-488000
-222.0%
400.0K
Operating Expenses
29.1M
+6.5%
27.3M
+16.0%
23.5M
+1.5%
23.2M
+17.6%
19.7M
R&D
9.6M
+42.4%
6.7M
+59.2%
4.2M
-29.1%
5.9M
-40.2%
9.9M
SG&A
19.5M
+3.8%
18.8M
-2.8%
19.3M
+12.6%
17.1M
+75.2%
9.8M
Operating Income
-23033000
-0.5%
-22911000
+4.6%
-24018000
-5.4%
-22792000
-15.5%
-19727000
EBITDA
-22343000
-1.3%
-22048000
+5.8%
-23410000
-5.2%
-22248000
-15.9%
-19193000
Net Income
-17075000
+16.5%
-20460000
-296.4%
-5161000
-104.7%
108.8M
+1004.8%
-12029000
EPS (Basic)
$-0.30
+28.6%
$-0.42
-320.0%
$-0.10
-104.8%
$2.07
+962.5%
$-0.24
EPS (Diluted)
$-0.30
+11.8%
$-0.34
-240.0%
$-0.10
-105.8%
$1.71
+812.5%
$-0.24
Shares (Diluted)
56.6M
-14.4%
66.1M
+21.9%
54.2M
-18.6%
66.6M
+33.9%
49.8M
Abeona Therapeutics (ABEO) — Financials